MLL-rearranged leukemias—an update on science and clinical approaches
AC Winters, KM Bernt - Frontiers in pediatrics, 2017 - frontiersin.org
The mixed-lineage leukemia 1 (MLL1) gene (now renamed Lysine [K]-specific
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of …
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of …
[HTML][HTML] The molecular biology of mixed lineage leukemia
RK Slany - Haematologica, 2009 - ncbi.nlm.nih.gov
Mixed lineage leukemia is a very aggressive blood cancer that predominantly occurs in
pediatric patients. In contrast to other types of childhood acute leukemias, mixed lineage …
pediatric patients. In contrast to other types of childhood acute leukemias, mixed lineage …
Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized …
R Pieters, P De Lorenzo, P Ancliffe… - Journal of clinical …, 2019 - ascopubs.org
PURPOSE Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A (MLL)
gene rearrangements and coexpression of myeloid markers. The Interfant-06 study …
gene rearrangements and coexpression of myeloid markers. The Interfant-06 study …
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo
Chromosomal translocations affecting mixed lineage leukemia gene (MLL) result in acute
leukemias resistant to therapy. The leukemogenic activity of MLL fusion proteins is …
leukemias resistant to therapy. The leukemogenic activity of MLL fusion proteins is …
A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial
D Tomizawa, T Miyamura, T Imamura… - Blood, The Journal …, 2020 - ashpublications.org
The prognosis for infants with acute lymphoblastic leukemia (ALL), particularly those with
KMT2A gene rearrangement (KMT2A-r), is dismal. Continuous efforts have been made in …
KMT2A gene rearrangement (KMT2A-r), is dismal. Continuous efforts have been made in …
How I treat infant leukemia
Leukemia in infants is rare but generates tremendous interest due to its aggressive clinical
presentation in a uniquely vulnerable host, its poor response to current therapies, and its …
presentation in a uniquely vulnerable host, its poor response to current therapies, and its …
Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins
Abstract Mixed lineage leukemia 1 (MLL1, also known as MLL or KMT2A) is an important
transcription factor and histone-H3 lysine-4 (H3K4) methyltransferase. It is a master …
transcription factor and histone-H3 lysine-4 (H3K4) methyltransferase. It is a master …
Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis
Abstract The RNA polymerase II (Pol II) elongation factor (ELL) was the first translocation
partner of mixed lineage leukaemia (MLL) for which a biochemical function was determined …
partner of mixed lineage leukaemia (MLL) for which a biochemical function was determined …
Biology and treatment of acute lymphoblastic leukemia
R Pieters, WL Carroll - Pediatric Clinics of North America, 2008 - Elsevier
Acute lymphoblastic leukemia (ALL), the most common type of cancer in children, is a
heterogeneous disease in which many genetic lesions result in the development of multiple …
heterogeneous disease in which many genetic lesions result in the development of multiple …
[HTML][HTML] Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond
CW Chen, SA Armstrong - Experimental hematology, 2015 - Elsevier
Highlights•The histone methyltransferase DOT1L is required for proliferation of mixed-
lineage leukemia gene (MLL)-rearranged leukemias.•DOT1L and H3K79 methylation …
lineage leukemia gene (MLL)-rearranged leukemias.•DOT1L and H3K79 methylation …